Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Anti-inflammatory drugs and DMARDs, especially methotrexate, have dramatically improved the outlook of RA patient. However, in some patients the treatment effect is still not satisfactory and needs to change therapeutic regimen in time. So, timely prediction of patient treatment effect is particularly important.
Methods: miRNAs are a large family of highly conserved noncoding genes and some of them become potential biomarker of disease diagnosis. Circulating miR-10a was detected by qRT-PCR. Receiver operating characteristic (ROC)curve analyses were performed for circulating miR-10a in RA diagnosis and predictor of therapy effectiveness in RA patients treated with methotrexate.
Results And Conclusion: In the present study, we found that the circulating miR-10a was significantly decreased in RA patients compared to osteoarthritic patients and healthy people. Importantly, circulating miR-10a was up-regulated in RA patients treated with MTX. Moreover, we identified circulating miR-10a that may serve as a biomarker of RA diagnosis and predictor of therapy effectiveness in rheumatoid arthritis patients treated with methotrexate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1389201019666180417155140 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum extracellular vesicle microRNAs as potential biomarkers to predict pembrolizumab response and prognosis in metastatic non-small cell lung cancer patients.
Front Immunol
June 2025
Laboratory of Preclinical and Translational Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture, Italy.
Introduction: Circulating Extracellular Vesicles (cEVs) could represent new non-invasive biomarkers for diagnosis and prognosis in tumors. In the context of Non-Small Cell Lung Cancer (NSCLC) immunotherapy there's a great need for novel predictive and prognostic biomarkers. This study aims to analyze cEVs microRNAs in serum of advanced stage NSCLC patients with PD-L1 expression ≥50% at diagnosis, before first-line pembrolizumab, to evaluate their possible role as potential biomarkers for immunotherapy response prediction and outcomes.
View Article and Find Full Text PDFElucidating the preventive and therapeutic effects of cardiac telocytes paracrine microRNAs on ischemic heart disease.
Front Cardiovasc Med
April 2025
Department of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Telocytes (TCs), a newly identified type of mesenchymal cell since 2010, possess substantial potential in maintaining tissue homeostasis, orchestrating organ development, and facilitating tissue regeneration. Their distribution in blood, the adventitia of blood vessels, and the intima implies a close association with vascular function. Ischemic heart disease (IHD), a significant challenge in cardiovascular disease, is characterized by the occlusion of major vessels, obstruction of collateral circulation, and disruption of the capillary network-pathological features closely linked to endothelial cell damage.
View Article and Find Full Text PDFmiRNA profile in pancreatic neuroendocrine tumors: Preliminary results.
Sci Prog
May 2025
Department of Endocrinology and Diabetes, Elias Hospital, Bucharest, Romania.
Objective: Our understanding of the pathophysiology of pancreatic neuroendocrine tumors (PanNETs) remains incomplete, largely due to their historically underestimated incidence and the perception of these tumors as rare and slow-growing cancers. Additionally, conventional reliance on histological examination alone is gradually being supplemented by the exploration and introduction of molecular biomarkers, such as microRNAs (miRNAs). As miRNAs modulate the expression of multiple genes and pathways involved in the tumorigenesis of PanNETs, these biomarkers hold considerable promise for diagnosis and prognosis applications.
View Article and Find Full Text PDFCan circulating microRNAs predict colorectal cancer? Results from a nested case-control study of pre-diagnostic serum samples from two prospective biobanks.
BMC Cancer
March 2025
Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Background: This study aimed to investigate the potential of circulating small RNAs (sRNAs) as predictive biomarkers for future colorectal cancer (CRC). The study analyzed serum samples from pre-diagnostic CRC patients in two prospective biobanks.
Methods: Serum samples from 142 pre-diagnostic CRC patients, from the Finnish Maternity Cohort (FMC) and The HUNT Study (HUNT2), were subjected to small RNA sequencing.
Prognostic Value of miR-10a-3p in Non-Small Cell Lung Cancer Patients.
Onco Targets Ther
November 2024
Laboratory of Molecular Oncology, National Cancer Institute, Vilnius, LT-08406, Lithuania.
Purpose: Poor lung cancer patients' outcomes and survival rates demand the discovery of new biomarkers for the specific, significant, and less invasive detection of non-small cell lung cancer (NSCLC) progression. The present study aimed to investigate the potential of miRNA expression as biomarkers in NSCLC utilizing a preclinical cell culture setup based on screening of miRNAs in NSCLC cells grown in 3D cell culture.
Patients And Methods: The study was performed using lung cancer cell lines, varying in different levels of aggressiveness: NCI-H1299, A549, Calu-1, and NCI-H23, as well as noncancerous bronchial epithelial cell line HBEC3, which were grown in 3D cell culture.